Icon (NASDAQ:ICLR) Azioni

Icon

Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

Icon PLC

TD Cowen analyst Charles Rhyee downgrades Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) from Buy to Hold and lowers the price target from $254 to $157.

News

Downgrades

Price Target

Analyst Ratings

ICLR

TD Cowen Downgrades Icon to Hold, Lowers Price Target to $157

Truist Securities analyst Jailendra Singh maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and lowers the price target from $262 to $208.

Truist Securities Maintains Buy on Icon, Lowers Price Target to $208

Barclays analyst Luke Sergott downgrades Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) from Overweight to Equal-Weight and lowers the price target from $240 to $165.

Barclays Downgrades Icon to Equal-Weight, Lowers Price Target to $165

Mizuho analyst Ann Hynes maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform and lowers the price target from $238 to $200.

Mizuho Maintains Outperform on Icon, Lowers Price Target to $200

Citigroup analyst Patrick Donnelly maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and lowers the price target from $290 to $215.

Citigroup Maintains Buy on Icon, Lowers Price Target to $215

Goldman Sachs analyst Matthew Sykes downgrades Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) from Buy to Neutral and lowers the price target from $250 to $200.

Goldman Sachs Downgrades Icon to Neutral, Lowers Price Target to $200

Baird analyst Eric Coldwell maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Neutral and lowers the price target from $221 to $203.

Baird Maintains Neutral on Icon, Lowers Price Target to $203

Contracts

Mural Health Technologies Enters Partnership With ICON To Utilize Mural Link For Trial Payments, Travel Support, And Communication Tools

WIIM

Icon shares are trading lower after the company announced delays in covid vaccine study.

Barclays analyst Luke Sergott maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Overweight and lowers the price target from $275 to $240.

Barclays Maintains Overweight on Icon, Lowers Price Target to $240

Editor's Note: This article has been updated to clarify that Elliott Investment Management purchased convertible senior notes of Wolfspeed and MicroStrategy.
Elliott Investment Management made several portfolio moves in the fourth quarter, closing multiple options positions and shaking up the activist firm&#8217;s <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43811538/5-top-tech-stocks-hedge-funds-have-been-bullish-on-in-q4-hint-its-not-nvidia">technology exposure</a>.
According to a new&nbsp;<a href="https://www.sec.gov/Archives/edgar/data/1791786/000101359425000294/xslForm13F_X02/primary_doc.xml" target="_blank" rel="noreferrer noopener">13-F</a>&nbsp;filing with the U.S. Securities and Exchange Commission, Elliott added the following new positions in the fourth quarter:
<ul>
<li>Wolfspeed Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) 0.25% and 1.875% convertible senior notes</li>
</ul>
<ul>
<li>NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) put options</li>
</ul>
<ul>
<li>SPDR Select Sector Fund Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) put options</li>
</ul>
<ul>
<li>SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOP#NYSE">XOP</a>) put options</li>
</ul>
Here's a look at all of the positions Elliott added to during the fourth quarter:
<ul>
<li>Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) increased by 369%</li>
</ul>
<ul>
<li>MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) increased convertible senior notes by 200%</li>
</ul>
<ul>
<li>CorMedix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) increased by 85%</li>
</ul>
<ul>
<li>HDFC Bank Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HDB#NYSE">HDB</a>) increased by 6%</li>
</ul>
Here&#8217;s a look at all of the positions Elliott closed during the fourth quarter:
<ul>
<li>Catalent Inc (CTLC) </li>
</ul>
<ul>
<li>Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</li>
</ul>
<ul>
<li>Unity Software Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>)</li>
</ul>
<ul>
<li>BILL Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>)</li>
</ul>
Elliott closed out of calls in several names including Arm Holdings, American Airlines and Alaska Air Group. The firm also closed multiple put positions including Equinix, Hyatt Hotels and Host Hotels.
Here's a look at all of the positions Elliott trimmed during the fourth quarter:
<ul>
<li>ICON Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) decreased by 62%</li>
</ul>
<ul>
<li>RingCentral Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RING#NYSE">RING</a>) decreased by 55%</li>
</ul>
<ul>
<li>NRG Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) decreased by 50%</li>
</ul>
<ul>
<li>Confluent Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) decreased by 37%</li>
</ul>
<ul>
<li>Southwest Airlines Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) decreased by 2%</li>
</ul>
The above information does not include call or put options that were added to or trimmed&nbsp;during the quarter.
This information was gathered using comparison tools from&nbsp;<a href="https://13f.info/13f/000101359425000294/compare/000101359424000968" target="_blank" rel="noreferrer noopener">13f.info</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43811538/5-top-tech-stocks-hedge-funds-have-been-bullish-on-in-q4-hint-its-not-nvidia">5 Top Tech Stocks Hedge Funds Have Been Bullish On In Q4 (Hint: It&#8217;s Not Nvidia)</a></li>
</ul>
This illustration was generated using artificial intelligence via Midjourney.

Hedge Funds

Trading Ideas

BILL

CFLT

CRMD

MSTR

NVDA

RING

WOLF

Elliott Investment Management Bets Against Nvidia In Q4 (CORRECTED)

Icon shares are trading higher after the company reported Q4 financial results and beat its adjusted EPS estimate.

Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) reported quarterly earnings of $3.43 per share which beat the analyst consensus estimate of $3.42 by 0.29 percent. This is a 0.87 percent decrease over earnings of $3.46 per share from the same period last year. The company reported quarterly sales of $2.04 billion which met the analyst consensus estimate. This is a 1.22 percent decrease over sales of $2.07 billion the same period last year.

Earnings

Earnings Beats

Icon Q4 2024 Adj EPS $3.43 Beats $3.42 Estimate, Sales $2.04B Inline

ACVA

AMPL

ANSS

APPN

BLCO

BMRN

BORR

CAKE

CCAP

CCSI

CHDN

CLVT

CMTG

CVNA

CWAN

ENLT

ENVX

ESRT

ETSY

EXAS

FOLD

First Trust Advantage Preferred Income Fund

FVRR

GLBE

GRAB

GRMN

HSBC

IIPR

IMAX

INSG

IONS

KALU

KPTI

KRYS

KVYO

LAND

LILA

LILAK

LOPE

LUNG

MANU

MATV

MGRC

MTRN

NDSN

NRDS

NYMT

OBDC

PAAS

PERI

PNST

PRAA

Earnings Scheduled For February 19, 2025

Truist Securities analyst Jailendra Singh maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Buy and lowers the price target from $284 to $262.

Truist Securities Maintains Buy on Icon, Lowers Price Target to $262

JP Morgan analyst Casey Woodring maintains Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Overweight and lowers the price target from $280 to $265.

JP Morgan Maintains Overweight on Icon, Lowers Price Target to $265

These eleven large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>FTAI Aviation Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NASDAQ">FTAI</a>) shares plummeted 35.42% after short seller firm Muddy Waters Research announced they <a href="https://www.benzinga.com//node/43040046" target="_blank" rel="noreferrer noopener">initiated a short position in the company</a>.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) stock plunged 19.38% after the company updated its 2025 expected revenue range to $1.5 billion to $2.5 billion, below <a href="https://www.benzinga.com//node/42946454" target="_blank" rel="noreferrer noopener">analyst estimates of $2.951 billion</a>. Morgan Stanley maintained an Equal-Weight rating and lowered the <a href="https://www.benzinga.com/quote/mrna/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $70 to $38</a>.</li>
<li>GameStop Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) stock declined 14.86%. In a recent X post, CNBC's Jim Cramer <a href="https://www.benzinga.com//node/43053808" target="_blank" rel="noreferrer noopener">steered investors toward</a> quantum stocks, suggesting they reinvest gains from GameStop into Rigetti Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>).</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) shares dipped 12.91% following a report suggesting that Trump is considering an executive order to save TikTok from a U.S. ban.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) shares were down 10.81%. The company disclosed that its second Pioneer spacecraft for Varda Space Industries, Inc. is<a href="https://www.benzinga.com//node/43028933" target="_blank" rel="noreferrer noopener"> successfully operating in orbit</a>.</li>
<li>Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) stock lost 9.51% last week despite Guggenheim <a href="https://www.benzinga.com/quote/ntra/analyst-ratings" target="_blank" rel="noreferrer noopener">raising the price forecast</a> from $170 to $200. The company is due to provide a roadmap and outlook at the J.P. Morgan Healthcare Conference.</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) stock decreased 9.27%  after the company issued FY24 revenue guidance <a href="https://www.benzinga.com//node/42976923" target="_blank" rel="noreferrer noopener">below the previous estimate</a>.</li>
<li>ICON plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) stock fell 9.22% after the company issued FY25 guidance with <a href="https://www.benzinga.com//node/42971328" target="_blank" rel="noreferrer noopener">its midpoint below estimates</a>.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) shares declined 8.89% after Moderna issued 2025 revenue <a href="https://www.benzinga.com//node/42951363" target="_blank" rel="noreferrer noopener">guidance below analyst estimates</a>.</li>
<li>Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) shares fell 8.89% after Ozempic and Wegovy were included in a list of 15 medications for <a href="https://www.benzinga.com//node/43062779" target="_blank" rel="noreferrer noopener">Medicare drug price negotiations</a>.</li>
<li>BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) shares tumbled 8.68%. The company initiated a legal action against Ascendis Pharma A/S for infringement of European patent EP 3 175 863 B1 at the <a href="https://www.benzinga.com//node/42953403" target="_blank" rel="noreferrer noopener">Unified Patent Court (UPC) in Munich, Germany</a>.</li>
</ol>
Photos courtesy: Shutterstock

Equities

Large Cap

Short Sellers

Movers

BNTX

FTAI

MRNA

NTRA

RGTI

RKLB

SNAP

Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?

RBC Capital analyst Sean Dodge reiterates Icon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLR#NASDAQ">ICLR</a>) with a Outperform and maintains $263 price target.

Reiteration

RBC Capital Reiterates Outperform on Icon, Maintains $263 Price Target

ICON shares are trading lower after the company issued FY25 guidance with its midpoint below estimates.

Guidance

ICON Earlier Issued Guidance; Sees FY25 Revenue $8.05B-$8.65B vs $8.496B Est., Adj. EPS $13.00-$15.00 vs $14.83 Est.

Press Releases

ICON 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against ICON plc - ICLR

ICLR Deadline: ICLR Purchasers Have Opportunity to Lead ICON plc Securities Fraud Lawsuit

FRIDAY INVESTOR DEADLINE: ICON PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Deadline Soon: ICON plc (ICLR) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

Legal

Lost Money on ICON Public Limited Company (ICLR)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm

The Gross Law Firm Reminds ICON  Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 11, 2025 - ICLR

ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

ICON Public Limited Company Class Action: Levi & Korsinsky Reminds ICON Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 11, 2025 – ICLR

Class Action Filed Against ICON Public Limited Company (ICLR) Seeking Recovery for Investors - Contact Levi & Korsinsky

ICLR Investors Have Opportunity to Lead ICON Public Limited Company Securities Fraud Lawsuit with the Schall Law Firm

Comments

Icon

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO